Document Detail

The NAD(P)H oxidase inhibitor apocynin improves endothelial NO/superoxide balance and lowers effectively blood pressure in spontaneously hypertensive rats: comparison to calcium channel blockade.
MedLine Citation:
PMID:  17653964     Owner:  NLM     Status:  MEDLINE    
The vascular NAD(P)H oxidase contributes to endothelial dysfunction and high blood pressure in the spontaneously hypertensive rat by enhancing superoxide production. We investigated the effects of apocynin, a NAD(P)H oxidase inhibitor, on blood pressure and vascular radical and nitric oxide formation in SHR and compared its effects to the calcium channel blocker nifedipine. Apocynin (over four weeks) lowered systolic blood pressure significantly and as effectively as nifedipine. Both apocynin and nifedipine significantly reduced superoxide production. In parallel, vascular nitric oxide production and ecNOS activity was significantly increased by apocynin treatment. Therefore, apocynin may be an effective antihypertensive drug in essential hypertension.
Anselm T Bäumer; Christian A Krüger; Juliane Falkenberg; Henrik Ten Freyhaus; Renate Rösen; Klaus Fink; Stephan Rosenkranz
Related Documents :
966384 - Hypotensive action and increased plasma renin activity by ca2+ antagonist (nifedipine) ...
2846214 - Enalapril & nifedipine in essential hypertension; synergism of the hypotensive effects ...
8512104 - Effects of nifedipine with isoflurane, halothane, or enflurane on automaticity, conduct...
11875324 - Twenty-four hour ambulatory blood pressure in the international nifedipine gits study i...
23839074 - The effect of positive end-expiratory pressure and tripled tidal volume on pleth variab...
10835294 - Blood pressure changes after intravenous administration of cell-free hemoglobin a and h...
Publication Detail:
Type:  Comparative Study; In Vitro; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical and experimental hypertension (New York, N.Y. : 1993)     Volume:  29     ISSN:  1064-1963     ISO Abbreviation:  Clin. Exp. Hypertens.     Publication Date:  2007 Jul 
Date Detail:
Created Date:  2007-07-26     Completed Date:  2007-09-14     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9305929     Medline TA:  Clin Exp Hypertens     Country:  United States    
Other Details:
Languages:  eng     Pagination:  287-99     Citation Subset:  IM    
Klinik III für Innere Medizin, Universität zu Köln, Köln, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acetophenones / pharmacology*
Blood Pressure / drug effects
Calcium Channel Blockers / pharmacology
Endothelium, Vascular / drug effects,  metabolism
Enzyme Inhibitors / pharmacology*
Hypertension / drug therapy*,  physiopathology*
NADPH Oxidase / antagonists & inhibitors*
Nifedipine / pharmacology
Nitric Oxide / metabolism
Nitric Oxide Synthase Type III / metabolism
Rats, Inbred SHR
Reactive Oxygen Species / metabolism
Superoxide Dismutase / metabolism
Vasoconstriction / drug effects
Reg. No./Substance:
0/Acetophenones; 0/Calcium Channel Blockers; 0/Enzyme Inhibitors; 0/Reactive Oxygen Species; 10102-43-9/Nitric Oxide; 21829-25-4/Nifedipine; 498-02-2/acetovanillone; EC Oxide Synthase Type III; EC protein, rat; EC Dismutase; EC Oxidase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Role of long-term potentiation of sympathetic ganglia (gLTP) in hypertension.
Next Document:  Cardiovascular reactivity in patients with essential or renal hypertension under standardized mental...